Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 15, 2024

SELL
$8.6 - $18.18 $13,364 - $28,251
-1,554 Reduced 8.91%
15,883 $288,000
Q4 2023

Jan 05, 2024

BUY
$4.55 - $9.9 $20,115 - $43,767
4,421 Added 33.97%
17,437 $172,000
Q3 2023

Oct 18, 2023

SELL
$6.72 - $8.6 $42,141 - $53,930
-6,271 Reduced 32.51%
13,016 $87,000
Q2 2023

Jul 20, 2023

BUY
$3.95 - $7.74 $76,183 - $149,281
19,287 New
19,287 $144,000

Others Institutions Holding MOR

About MorphoSys AG


  • Ticker MOR
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 136,614,000
  • Description
  • MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...
More about MOR
Track This Portfolio

Track Exchange Traded Concepts, LLC Portfolio

Follow Exchange Traded Concepts, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exchange Traded Concepts, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Exchange Traded Concepts, LLC with notifications on news.